Loviride
 | |
| Clinical data | |
|---|---|
| ATC code | None |
| Identifiers | |
| |
| Synonyms | R089439 |
| CAS Number |
147362-57-0  |
| PubChem (CID) | 3963 |
| ChemSpider |
3826  |
| UNII |
3S1R1LZ09H |
| KEGG |
D04786 |
| ChEMBL |
CHEMBL37624 |
| Chemical and physical data | |
| Formula | C17H16Cl2N2O2 |
| Molar mass | 351.227 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| (what is this?) (verify) | |
Loviride (also called loveride) was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is an Non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance the NNRTIs efavirenz and nevirapine.
Synthesis
Loviride synthesis: Janssen Pharmaceutica U.S. Patent 5,407,961 (1995).
External links
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.